+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Conjugated Monoclonal Antibodies Global Market Report 2022: By Drugs, By Technology, By Application

  • PDF Icon

    Report

  • 400 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553722
Conjugated Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global conjugated monoclonal antibodies market.



This report focuses on conjugated monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the conjugated monoclonal antibodies market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the conjugated monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Conjugated Monoclonal Antibodies market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider conjugated monoclonal antibodies market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
  • The conjugated monoclonal antibodies market section of the report gives context. It compares the conjugated monoclonal antibodies market with other segments of the conjugated monoclonal antibodies market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, conjugated monoclonal antibodies indicators comparison

Scope


Markets Covered:


1) By Drugs: Adcetris; Kadcyla
2) By Technology: Cleavable Linker; Non-cleavable Linker
3) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumour; Others

Companies Mentioned:Pfizer Inc.; F. Hoffmann-LA; Bristol -Myers Squibb; Merck & Co. Inc.; Immunomedics Inc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Frequently Asked Questions about the Global Conjugated Monoclonal Antibodies Market

What is the estimated value of the Global Conjugated Monoclonal Antibodies Market?

The Global Conjugated Monoclonal Antibodies Market was estimated to be valued at $9.64 billion in 2022.

What is the growth rate of the Global Conjugated Monoclonal Antibodies Market?

The growth rate of the Global Conjugated Monoclonal Antibodies Market is 5.8%, with an estimated value of $12.09 billion by 2026.

What is the forecasted size of the Global Conjugated Monoclonal Antibodies Market?

The Global Conjugated Monoclonal Antibodies Market is estimated to be worth $12.09 billion by 2026.

Who are the key companies in the Global Conjugated Monoclonal Antibodies Market?

Key companies in the Global Conjugated Monoclonal Antibodies Market include Pfizer inc., F.Hoffmann, LA, Bristol, Myers Squibb, Merck & Co. inc., Immunomedics inc., Takeda Pharmaceuticals Industries Ltd. and Actinium Pharmaceutical.

Table of Contents

1. Executive Summary2. Conjugated Monoclonal Antibodies Market Characteristics3. Conjugated Monoclonal Antibodies Market Trends And Strategies4. Impact Of COVID-19 On Conjugated Monoclonal Antibodies
5. Conjugated Monoclonal Antibodies Market Size And Growth
5.1. Global Conjugated Monoclonal Antibodies Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Conjugated Monoclonal Antibodies Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Conjugated Monoclonal Antibodies Market Segmentation
6.1. Global Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Adcetris
  • Kadcyla
6.2. Global Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Cleavable Linker
  • Non-cleavable Linker
6.3. Global Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumour
  • Others

7. Conjugated Monoclonal Antibodies Market Regional And Country Analysis
7.1. Global Conjugated Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Conjugated Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Conjugated Monoclonal Antibodies Market
8.1. Asia-Pacific Conjugated Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Conjugated Monoclonal Antibodies Market
9.1. China Conjugated Monoclonal Antibodies Market Overview
9.2. China Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Conjugated Monoclonal Antibodies Market
10.1. India Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Conjugated Monoclonal Antibodies Market
11.1. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Conjugated Monoclonal Antibodies Market
12.1. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Conjugated Monoclonal Antibodies Market
13.1. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Conjugated Monoclonal Antibodies Market
14.1. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Conjugated Monoclonal Antibodies Market
15.1. Western Europe Conjugated Monoclonal Antibodies Market Overview
15.2. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Conjugated Monoclonal Antibodies Market
16.1. UK Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Conjugated Monoclonal Antibodies Market
17.1. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Conjugated Monoclonal Antibodies Market
18.4. France Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Conjugated Monoclonal Antibodies Market
19.1. Eastern Europe Conjugated Monoclonal Antibodies Market Overview
19.2. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Conjugated Monoclonal Antibodies Market
20.1. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Conjugated Monoclonal Antibodies Market
21.1. North America Conjugated Monoclonal Antibodies Market Overview
21.2. North America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Conjugated Monoclonal Antibodies Market
22.1. USA Conjugated Monoclonal Antibodies Market Overview
22.2. USA Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Conjugated Monoclonal Antibodies Market
23.1. South America Conjugated Monoclonal Antibodies Market Overview
23.2. South America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Conjugated Monoclonal Antibodies Market
24.1. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Conjugated Monoclonal Antibodies Market
25.1. Middle East Conjugated Monoclonal Antibodies Market Overview
25.2. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Conjugated Monoclonal Antibodies Market
26.1. Africa Conjugated Monoclonal Antibodies Market Overview
26.2. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Conjugated Monoclonal Antibodies Market Competitive Landscape And Company Profiles
27.1. Conjugated Monoclonal Antibodies Market Competitive Landscape
27.2. Conjugated Monoclonal Antibodies Market Company Profiles
27.2.1. Pfizer Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. F. Hoffmann-LA
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Bristol -Myers Squibb
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Merck & Co. Inc.
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Immunomedics Inc.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Conjugated Monoclonal Antibodies Pipeline Analysis29. Key Mergers And Acquisitions In The Conjugated Monoclonal Antibodies Market30. Conjugated Monoclonal Antibodies Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the conjugated monoclonal antibodies market are Pfizer Inc., F. Hoffmann-LA, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., and Spectrum Pharmaceuticals Inc.

The global conjugated monoclonal antibodies market is expected to grow from $8.89 billion in 2021 to $9.64 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $12.09 billion in 2026 at a CAGR of 5.8%.

North The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies. Conjugated monoclonal antibodies are monoclonal antibodies (mAbs) associated with a chemotherapy drug or a radioactive particle. These are used in the treatment of cancer as they deliver the toxic substance directly to the tumor cells by reducing damage to normal cells in other parts of the body.

The main types of drugs in conjugated monoclonal antibodies are adcetris and kadcyla. Adcetris is a brand-name pharmaceutical drug intended to cure adults with certain types of lymphoma. Lymphoma is a cancer which attacks the lymphatic system and lymphocytes, that are white blood cells. The different technologies include cleavable linker, non-cleavable linker and is used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumour, others.

America was the largest region in the conjugated monoclonal antibodies market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing popularity and therapeutic potential of conjugated monoclonal antibodies especially antibody-drug conjugate is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs), are class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumor cells, predominantly used in the treatment of cancer. The U.S. Food and Drug Administration approved only five antibody-drug conjugates drugs till 2018 and in 2019, it has approved three antibody-drug conjugates drugs indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies mainly in the field of cancer which in turn aids in the growth of the market.

The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market. For instance, the cost of the first FDA approved radioimmunotherapy drug Yttrium 90 Ibritumomab Tiuxetan therapeutic (Zevalin) is priced at around $55,000. Moreover, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas which was approved in December 2019 cost between $110,000 to $120,000 for a course of treatment. The high cost of the therapy makes it unaffordable for the patients and healthcare systems of underdeveloped countries which hinders the growth of the conjugated monoclonal antibodies market.

Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies shaping the market. For instance, in October 2019 NovoCodex, a subsidiary of Zhejiang Medicine Co Ltd collaborated for the second time with Ambrx Inc, a USA-based company engaged in developing protein therapeutics to develop and commercialize Ambrx's internally developed site-specific antibody-drug conjugate, ARX305 used for the treatment of CD70 positive cancers. Following the trend, in June 2020, Monopar Therapeutics, a USA-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered in collaboration to couple Monopar’s MNPR-101 a humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage to a therapeutic radioisotope of NorthStar to create a highly selective agent, which has the potential to kill aberrantly activated cytokine-producing immune cells.

In July 2020, AstraZeneca, a UK-based drugmaker has entered into a partnership with Daiichi Sankyo for an amount of $6 billion. This deal is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC) which is a type of drug that works by using a monoclonal antibody to deliver an attached pharmaceutical payload directly to tumor cells. Daiichi Sankyo is a Japanese based pharmaceutical company engaged in the development of antibody-drug conjugates.

The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer inc.
  • F.Hoffmann-LA
  • Bristol -Myers Squibb
  • Merck & Co. inc.
  • Immunomedics inc.
  • Takeda Pharmaceuticals Industries Ltd.
  • Daiichi Sankyo Company Limited
  • Actinium Pharmaceutical
  • Nordic Nanovector inc.
  • Spectrum Pharmaceuticals inc.
  • AbbVie inc.
  • Roche Ltd.
  • Bayer AG
  • AstraZeneca
  • Novartis AG

Methodology

Loading
LOADING...